ASH 2016 | CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients
Stephan Grupp, MD, PhD, from the Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the results of a global registration trial (NCT02435849) of the efficacy and safety of CTL019 in pediatric patients and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) at the American Society of Hematology (ASH) Congress 2016 in San Diego, CA. This is the first global trial for a cell therapy in this patient group. Dr Grupp explains that CAR-T-cells, which have been in development for a number of years, are engineered T-cells which can potentially attack cancer, and significant clinical results have been seen in a single-institution trial. In this trial, involving 25 centers in 11 countries, the safety and efficacy of CTL019 was assessed in high-risk relapsed and refractory pediatric and young adult ALL patients. Dr Grupp summarises the results of this study, which showed an initial complete response (CR) rate of 82%, and an overall survival (OS) at 6 months of 89%, with results very similar to the single institution trial. CTL019 was delivered with a high level of safety, and cytokine release syndrome (CRS) was well-managed due to extensive training programs for physicians, with no CRS-associated deaths in the trial. He concludes that from both an efficacy and safety standpoint, the global registration trial worked out well.
Get great new content delivered to your inboxSign up